TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8469621

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg 3 times/day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Aspirin 650 mg 3 times/day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Acetaminophen 650 mg 3 times/day
Number of subjects: 25
Study: 3086261

Group type: EXPERIMENTAL
Intervention: Lactose-restricted diet
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Lactase group (milk with lactase enzyme)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (regular diet with milk)
Number of subjects: 64
Study: 3219992

Group type: EXPERIMENTAL
Intervention: Drug information sheets issued
Number of subjects: 107

Group type: COMPARATOR
Intervention: No drug information sheets issued
Number of subjects: 107
Study: 30755470

Group type: EXPERIMENTAL
Intervention: Unhealthy dietary pattern
Number of subjects: 320

Group type: COMPARATOR
Intervention: Healthy dietary pattern
Number of subjects: 320

Group type: COMPARATOR
Intervention: Traditional dietary pattern
Number of subjects: 320
Study: 29432399

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 92

Group type: COMPARATOR
Intervention: Radiofrequency ablation
Number of subjects: 92
Study: 29122787

Group type: EXPERIMENTAL
Intervention: Octenidine-impregnated wash mitts
Number of subjects: 225000

Group type: COMPARATOR
Intervention: Placebo wash mitts
Number of subjects: 225000
Study: 26630143

Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 6068

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6068
Study: 23360122

Group type: EXPERIMENTAL
Intervention: Automated analysis of colonic manometry data
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Comparison between patients and controls
Number of subjects: 17
Study: 21146881

Group type: COMPARATOR
Intervention: Bedtime NPH
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Bedtime glargine
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Morning glargine
Number of subjects: 85
Study: 18617122

Group type: EXPERIMENTAL
Intervention: Propofol, 1 mg/kg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Landiolol, 0.1 mg/kg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nicardipine, 1 mg
Number of subjects: 27
Study: 16598373

Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/day
Number of subjects: 5082

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5082
Study: 12600337

Group type: EXPERIMENTAL
Intervention: First perturbation
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Second perturbation
Number of subjects: 44
Study: 10834523

Group type: EXPERIMENTAL
Intervention: Ibuprofen lysine (10 mg/kg), followed by 5 mg/kg after 24 h and 48 h
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ibuprofen prophylaxis
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Indomethacin treatment
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Surgical ligation
Number of subjects: 46
Study: 9087158

Group type: EXPERIMENTAL
Intervention: Clemastine (0.5 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8227846

Group type: COMPARATOR
Intervention: Conventional loading dose of amiodarone (600 mg twice a day for 10 days)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High loading dose of amiodarone (50 mg/kg per day on days 1-3, 30 mg/kg per day on days 4-5, and 600 mg twice a day on days 6-10)
Number of subjects: 32
Study: 3456945

Group type: EXPERIMENTAL
Intervention: 15(R)‐15‐methyl prostaglandin E2 (PGE2)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29673374

Group type: EXPERIMENTAL
Intervention: Announcement training
Number of subjects: 83

Group type: COMPARATOR
Intervention: Conversation training
Number of subjects: 83
Study: 28659053

Group type: EXPERIMENTAL
Intervention: Posterior approach (group I)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Anterolateral approach (group II)
Number of subjects: 68
Study: 26769839

Group type: EXPERIMENTAL
Intervention: FiO2 1.0 for 60 minutes
Number of subjects: 24

Group type: COMPARATOR
Intervention: FiO2 0.4 for 60 minutes
Number of subjects: 24
Study: 23791232

Group type: EXPERIMENTAL
Intervention: Very early feeding regimen (within 24 hours of birth)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Delayed feeding regimen (after 24 hours of birth)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Very early feeding regimen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Delayed feeding regimen
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both feeding regimens
Number of subjects: 60
Study: 21417807

Group type: EXPERIMENTAL
Intervention: Meditation (20 minutes of guided meditation)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Meditation (20 minutes of guided meditation before stress)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (waiting quietly for an equivalent period of meditation time)
Number of subjects: 32
Study: 19043153

Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5-20 mg/day)
Number of subjects: 314
Study: 17012527

Group type: EXPERIMENTAL
Intervention: Naltrexone (opioid antagonist)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12680739

Group type: EXPERIMENTAL
Intervention: (S)-ketamine (subanaesthetic doses)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10853206

Group type: EXPERIMENTAL
Intervention: Propofol at subhypnotic dose (1.0 mg/kg/h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (Intralipid)
Number of subjects: 60
Study: 9358126

Group type: EXPERIMENTAL
Intervention: Desirudin (15 mg subcutaneously twice daily)
Number of subjects: 2079

Group type: COMPARATOR
Intervention: Enoxaparin (40 mg subcutaneously once daily)
Number of subjects: 2079

Group type: EXPERIMENTAL
Intervention: Desirudin
Number of subjects: 2079

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 2079
Study: 8415497

Group type: EXPERIMENTAL
Intervention: Drug prevention program with 11 lessons (8 in grade 7 and 3 in grade 8), taught by adult teachers and older teens in some schools.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Drug prevention program taught by adults without teen leaders.
Number of subjects: 30

Group type: COMPARATOR
Intervention: All treatment conditions (both groups).
Number of subjects: 30
Study: 3463568

Group type: EXPERIMENTAL
Intervention: Standard remission induction treatment
Number of subjects: 738
Study: 29952639

Group type: EXPERIMENTAL
Intervention: Vibratory stimulation device (DentalVibe)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional techniques
Number of subjects: 32
Study: 28166840

Group type: EXPERIMENTAL
Intervention: e‐learning with the serious gaming app Touch Surgery (TM) for chest drain insertion
Number of subjects: 90

Group type: COMPARATOR
Intervention: serious gaming for an unrelated procedure
Number of subjects: 90
Study: 26132315

Group type: EXPERIMENTAL
Intervention: Conventional surgery
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided foam sclerotherapy (UGFS)
Number of subjects: 224
Study: 24080592

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 20498621

Group type: EXPERIMENTAL
Intervention: Nutraceuticals (NUTs)
Number of subjects: 1380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1380
Study: 19000554

Group type: EXPERIMENTAL
Intervention: trans-resveratrol (400 mg) after a standard high fat content meal
Number of subjects: 24

Group type: COMPARATOR
Intervention: trans-resveratrol (400 mg) after 8 hours of fasting
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Comparison of fed vs fasting conditions for Cmax
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Comparison of fed vs fasting conditions for AUC0- yen
Number of subjects: 24
Study: 16357550

Group type: EXPERIMENTAL
Intervention: Progressively increased high-intensity aerobic exercise (n = 12)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 22
Study: 12836810

Group type: EXPERIMENTAL
Intervention: sibutramine 10 mg once a day
Number of subjects: 57

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 57
Study: 11144703

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled-release/extended-release metoprolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: β-blockers (general)
Number of subjects: 0
Study: 8909907

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 1683929

Group type: EXPERIMENTAL
Intervention: HyperCritic computer program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Panel of eight physicians
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HyperCritic
Number of subjects: 20

Group type: COMPARATOR
Intervention: Physician reviewers
Number of subjects: 20
Study: 6121181

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) enemas
Number of subjects: 9

Group type: COMPARATOR
Intervention: Betamethasone enemas
Number of subjects: 9
Study: 30661690

Group type: EXPERIMENTAL
Intervention: Yacon flour (25 g daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 26
Study: 28494116

Group type: EXPERIMENTAL
Intervention: Oscillating-rotating power toothbrush
Number of subjects: 41

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 41
Study: 25534388

Group type: EXPERIMENTAL
Intervention: 8 weeks of androgen suppression (AS) followed by radiotherapy with an additional 8 weeks of concurrent AS (16 weeks total)
Number of subjects: 1579

Group type: EXPERIMENTAL
Intervention: 28 weeks of androgen suppression (AS) followed by radiotherapy with an additional 8 weeks of AS (36 weeks total)
Number of subjects: 1579
Study: 23233383

Group type: EXPERIMENTAL
Intervention: MRI model
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: CT model
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Imaging criteria for favorable penumbral pattern
Number of subjects: 66
Study: 21805159

Group type: EXPERIMENTAL
Intervention: CPAP plus standard treatment
Number of subjects: 207

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 207
Study: 18779759

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Caloric Restriction (CR)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Caloric Restriction + Resistance Training (CR + RT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 48
Study: 16702494

Group type: EXPERIMENTAL
Intervention: Dexamethasone pulse (DP) therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo pulse (PP) therapy
Number of subjects: 20
Study: 15611396

Group type: EXPERIMENTAL
Intervention: Butterbur Ze339 high dose (1 tablet 3 times daily)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Butterbur Ze339 low dose (1 tablet twice daily)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Butterbur Ze339 (both doses)
Number of subjects: 186
Study: 11732835

Group type: EXPERIMENTAL
Intervention: Modified constraint induced therapy (CIT)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Regular therapy
Number of subjects: 6

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 6
Study: 9129379

Group type: EXPERIMENTAL
Intervention: Group hypnosis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group 1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group 2
Number of subjects: 30
Study: 8678251

Group type: EXPERIMENTAL
Intervention: 300 IU.kg‐1 of heparin before bypass
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 600 IU.kg‐1 of heparin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 300 IU.kg‐1 of heparin as bolus followed by a continuous infusion of 10 000 IU.h‐1 until the end of bypass
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 600 IU.kg‐1 of heparin plus high dose aprotinin (2 million IU of aprotinin before bypass, 500 000 IU.h‐1 until the end of the operation and 2 million IU added to the bypass pump prime)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study: 2080791

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human erythropoietin (r‐HuEPO)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human erythropoietin (r‐HuEPO)
Number of subjects: 12
Study: 395958

Group type: EXPERIMENTAL
Intervention: Creatinol O-phosphate (COP)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Reference substance (solvent of COP)
Number of subjects: 25
Study: 30728415

Group type: EXPERIMENTAL
Intervention: Buried-knot technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Continuous loop technique
Number of subjects: 30
Study: 28717899

Group type: EXPERIMENTAL
Intervention: Physicians who received no payments ($0)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Physicians who received payments over $13,000
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Participants who found their own physician on the website
Number of subjects: 278

Group type: COMPARATOR
Intervention: Control arm (did not view the disclosure website)
Number of subjects: 278
Study: 25829156

Group type: EXPERIMENTAL
Intervention: Decompression
Number of subjects: 20

Group type: COMPARATOR
Intervention: Neurectomy
Number of subjects: 20
Study: 25022774

Group type: EXPERIMENTAL
Intervention: Acceptance-based training (60-90 minutes)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined pre- to posttreatment data for all participants
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acceptance and Action Questionnaire‐II (AAQ‐II)
Number of subjects: 30
Study: 22292861

Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Loss-framed messages
Number of subjects: 148

Group type: COMPARATOR
Intervention: All message frames
Number of subjects: 148
Study: 20119585

Group type: EXPERIMENTAL
Intervention: 2% lidocaine/100 microg fentanyl/epinephrine
Number of subjects: 61

Group type: COMPARATOR
Intervention: 2% lidocaine/saline/epinephrine
Number of subjects: 61
Study: 17434069

Group type: EXPERIMENTAL
Intervention: Educational brochure
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Educational conversation with a trained mammography technologist
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Brochure together with the conversation with a trained technologist
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 198
Study: 15808032

Group type: EXPERIMENTAL
Intervention: Quinine sulphate
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 11991886

Group type: EXPERIMENTAL
Intervention: Albuterol nebulized with heliox
Number of subjects: 45

Group type: COMPARATOR
Intervention: Albuterol nebulized with oxygen (control)
Number of subjects: 45
Study: 9438623

Group type: EXPERIMENTAL
Intervention: Totally preperitoneal (TPP) laparoscopic approach
Number of subjects: 100

Group type: COMPARATOR
Intervention: Stoppa procedure (open)
Number of subjects: 100
Study: 8192293

Group type: EXPERIMENTAL
Intervention: Cochrane Collaboration systematic reviews of RCTs
Number of subjects: 0
Study: 2949023

Group type: EXPERIMENTAL
Intervention: Foscarnet cream (0.3% in men and 1% in women)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study: 30513892

Group type: EXPERIMENTAL
Intervention: PED-t
Number of subjects: 164

Group type: COMPARATOR
Intervention: CBT
Number of subjects: 164
Study: 26662998

Group type: EXPERIMENTAL
Intervention: Cardiopoietic stem cell therapy (600 × 10^6 bone marrow-derived and lineage-directed autologous cardiopoietic stem cells administered via a retention-enhanced intramyocardial injection catheter
Number of subjects: 240

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Cardiopoietic stem cell therapy
Number of subjects: 240
Study: 25070705

Group type: EXPERIMENTAL
Intervention: Provision of X-ray for remote consultation through an iPad
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard approach (verbal information only, no X-ray provided remotely)
Number of subjects: 42
Study: 22500711

Group type: EXPERIMENTAL
Intervention: Sanjie Zhitong plaster
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20577717

Group type: EXPERIMENTAL
Intervention: Buprenorphine (4, 8, and 16 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (4/1, 8/2, and 16/4 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of buprenorphine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone combination (low and high doses)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intramuscular hydromorphone (2 and 4 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Buprenorphine with naloxone
Number of subjects: 8
Study: 18607527

Group type: EXPERIMENTAL
Intervention: Nondirective supportive intervention (NDSI)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Directive visual motor intervention (DVMI)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 168
Study: 16491674

Group type: EXPERIMENTAL
Intervention: Knowledge of results provided for both arms in Experiment 1
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Knowledge of results provided for one arm only in Experiment 2
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Same distance movements with knowledge of results
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Different distance movements
Number of subjects: 64
Study: 11798998

Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 400

Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 400

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 400
Study: 10412778

Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein apheresis (LDL-A)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 27
Study: 7676822

Group type: EXPERIMENTAL
Intervention: Large collar prosthetic designs (Lubinus, HD2, Scanhip)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Flanged or tapered stem prosthetic designs (Charnley, Exeter)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Large collar prosthetic designs
Number of subjects: 204
Study: 1756688

Group type: EXPERIMENTAL
Intervention: Ofloxacin (400 mg 12 hourly)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Erythromycin (400 mg every 6 hours)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 52

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 52
Study: 7159502

Group type: EXPERIMENTAL
Intervention: ethinyl‐estradiol/noretisterone (EE/NET) 35 micrograms/0.5 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: ethinyl‐estradiol/noretisterone (EE/NET) 50 micrograms/1 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: ethinyl‐estradiol/noretisterone (EE/NET) 35 micrograms/1 mg
Number of subjects: 11
Study: 30412652

Group type: EXPERIMENTAL
Intervention: Static air support surfaces
Number of subjects: 308

Group type: COMPARATOR
Intervention: Alternating pressure air mattresses
Number of subjects: 308
Study: 29741911

Group type: EXPERIMENTAL
Intervention: Semitendinosus and Gracilis Tendon (STG) Autograft
Number of subjects: 64

Group type: COMPARATOR
Intervention: Patellar Tendon (PT) Autograft
Number of subjects: 64
Study: 27745818

Group type: EXPERIMENTAL
Intervention: Combination therapy with ambrisentan and tadalafil
Number of subjects: 605

Group type: COMPARATOR
Intervention: Monotherapy (ambrisentan or tadalafil)
Number of subjects: 605
Study: 24747412

Group type: EXPERIMENTAL
Intervention: Scaling and root planning (SRP)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planning (FMSRP)
Number of subjects: 29
Study: 22446022

Group type: EXPERIMENTAL
Intervention: Cetuximab added to chemotherapy
Number of subjects: 845

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 845
Study: 19329115

Group type: EXPERIMENTAL
Intervention: Expectant management after induced abortion with misoprostol (group 1)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Expectant management after spontaneous abortion (group 2)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 96
Study: 17504682

Group type: COMPARATOR
Intervention: Isoniazid 300 mg per day for 6 months (Group I)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Isoniazid 300 mg per day plus rifampin 600 mg per day for 3 months (Group II)
Number of subjects: 105
Study: 15167956

Group type: EXPERIMENTAL
Intervention: Group A (>= 4 attacks/week)
Number of subjects: 12
Study: 11245864

Group type: EXPERIMENTAL
Intervention: Individually planned care and systematic clinical supervision (Experimental Ward)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control Ward (no intervention)
Number of subjects: 22
Study: 9688409

Group type: EXPERIMENTAL
Intervention: Cetrorelix 60 mg administered i.m. on cycle day 2, followed by a second dose of either 30 or 60 mg based on oestradiol suppression
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cetrorelix
Number of subjects: 20
Study: 8134987

Group type: EXPERIMENTAL
Intervention: Continuous flow irrigation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intermittent flow irrigation
Number of subjects: 80
Study: 2642605

Group type: EXPERIMENTAL
Intervention: Methylprednisolone and chlorambucil
Number of subjects: 81

Group type: COMPARATOR
Intervention: Supportive therapy alone
Number of subjects: 81
Study: 870130

Group type: EXPERIMENTAL
Intervention: High dose synthetic human calcitonin (CIBA 47175‐Ba)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Radiographs and radioisotope bone scans
Number of subjects: 8